# UVA Licensing & Ventures Group

> UVA Licensing & Ventures Group is a VC fund backing Health Care. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Charlottesville, United States
- Total investments: 14
- Last investment: May 2024
- Lead investor: 36%
- Last updated: Aug 2026
- Website: https://lvg.virginia.edu/

UVA Licensing & Ventures Group is an investment firm.

## Contacts

5 contacts available for UVA Licensing & Ventures Group. Shizune tracks 2 team members at UVA Licensing & Ventures Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/uva-licensing-ventures-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 36% |
| Biotechnology | 4 | 29% |
| Medical | 3 | 21% |
| Therapeutics | 3 | 21% |
| Medical Device | 3 | 21% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 43% |
| Series A | 2 | 14% |
| Series B | 2 | 14% |
| Funding Round | 2 | 14% |
| Series C | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 64% |
| El Salvador | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Robert Creeden | Managing Director | 6 | — |
| Andrew J. Krouse | Entrepreneur-in-Residence | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NANOCHON | Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $4M | Seed | May 06, 2024 |  |
| BrightSpec | LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. | $18.4M | Series C | Dec 14, 2022 |  |
| GenEp | GenEp, Inc. is a pre-clinical stage biotechnology company based on intellectual property assets. GenEp creates therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. | $1.5M | Seed | Oct 26, 2021 |  |
| NANOCHON | Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $2M | Seed | Sep 16, 2021 |  |
| Mission Secure | Mission Secure®, an OT cybersecurity leader, is setting a new standard in OT cyber-protection stopping OT cyber threats head-on. The Mission Secure Platform backed by 24/7 Managed Services is the first to seamlessly integrate OT visibility, segmentation, protection, threat hunting, and incident response, delivering military strength,industrial grade OT protection. With Mission Secure, customers keep critical operations up and running and safe from harm. Learn more at https://www.missionsecure.com. | $5.6M | Series B | Jan 26, 2021 |  |
| Slate Bio | Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics. | $1.8M | Seed | Jan 19, 2021 |  |
| BrightSpec | LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. |  | Series B | Aug 01, 2020 |  |
| Merand Pharmaceuticals | Merand Pharmaceuticals develops a microRNA therapeutic to treat Peripheral Arterial Disease. Merand's therapeutic treats patients by promoting angiogenesis or the development of new blood vessels, which leads to restored blood flow, enabling doctors to stabilize functional blood vessels of patients to increase perfusion recovery and reduceinflammation. |  | Seed | Jul 31, 2019 |  |
| Direct Spinal Therapeutics | Direct Spinal Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business. The company was incorporated in 2013 and is based in Charlottesville, Virginia. |  |  | Jun 18, 2019 |  |
| Arrive Health | RxRevu is a physician-founded organization on a mission to become the leader in prescription decision support, helping prescribers identify the most cost-effective medications for each patient, at the point of care. RxRevu was referred to as the “Google of Drugs” by CNBC and is currently working with health systems, PBMs, and electronic healthrecords (EHR) vendors.RxRevu’s EHR-embedded technology allows prescribers to view prior authorizations and real-time, patient-specific cost and drug options aligned with formulary and benefit data. This information is provided directly from the payer/PBM to inform the prescriber before medication selection. In addition, the platform provides prescription health analytics to help organizations understand prescribing behavior and drive consistent prescribing practices in line with an organization's best practices. | $15.9M | Series A | May 31, 2019 |  |

10 of 14 investments shown.

## Co-investors
- [Blue Bear Capital](https://shizune.co/investors/profile/blue-bear-capital) — VC Fund, 2 deals together
- [CAV Angels](https://shizune.co/investors/profile/cav-angels) — VC Fund, 2 deals together
- [Chevron Technology Ventures](https://shizune.co/investors/profile/chevron-technology-ventures) — VC Fund, 2 deals together
- [Energy Innovation Capital](https://shizune.co/investors/profile/energy-innovation-capital) — VC Fund, 2 deals together
- [Felton Group LLC](https://shizune.co/investors/profile/felton-group-llc) — VC Fund, 2 deals together
- [Genoa Ventures](https://shizune.co/investors/profile/5-prime-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does UVA Licensing & Ventures Group invest in?

UVA Licensing & Ventures Group invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact UVA Licensing & Ventures Group?

Public channels for UVA Licensing & Ventures Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at UVA Licensing & Ventures Group?

The team at UVA Licensing & Ventures Group includes Robert Creeden (Managing Director) and Andrew J. Krouse (Entrepreneur-in-Residence). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co